2011
DOI: 10.2217/fca.11.54
|View full text |Cite
|
Sign up to set email alerts
|

Cardio-oncology in Targeting the Her Receptor Family: the Puzzle of Different Cardiotoxicities of HER2 Inhibitors

Abstract: The HER family of tyrosine kinase receptors includes several members that are clinically important targets in cancer therapies, in particular HER1 (the EGF receptor) and HER2, other members include HER3 and HER4. Trastuzumab, a humanized monoclonal antibody and lapatinib, a tyrosine kinase inhibitor, are drugs that target HER2, which is highly expressed in 20-30% of breast cancers. Trastuzumab is recommended as an adjuvant therapy for lymph node positive, HER2-positive breast cancers, or node-negative cancer w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
25
0
1

Year Published

2012
2012
2020
2020

Publication Types

Select...
5
3
1

Relationship

2
7

Authors

Journals

citations
Cited by 47 publications
(26 citation statements)
references
References 86 publications
0
25
0
1
Order By: Relevance
“…The mechanisms by which these agents affect calcium handling are not known. They may include doi: 10.7243/2052-4358-1-10 interference with downstream effector pathways, including PI3K/Akt, Ras/MEK/ERK and Src/FAK [1,2,7,22], and effects on function or expression of proteins involved in calcium release and uptake, such as RyR or SERCA2a.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The mechanisms by which these agents affect calcium handling are not known. They may include doi: 10.7243/2052-4358-1-10 interference with downstream effector pathways, including PI3K/Akt, Ras/MEK/ERK and Src/FAK [1,2,7,22], and effects on function or expression of proteins involved in calcium release and uptake, such as RyR or SERCA2a.…”
Section: Discussionmentioning
confidence: 99%
“…These agents have revolutionized breast cancer treatment [1,2]. Addition of trastuzumab to anthracycline-or taxane-based chemotherapy significantly improves response rate, time to progression, and survival in HER2-positive metastatic disease.…”
Section: Introductionmentioning
confidence: 99%
“…A meta-analysis showed that patients treated with trastuzumab were about 5 times more at risk of developing congestive heart failure in early breast cancer compared to patients not treated with this targeted therapy [43]. Nevertheless, if trastuzumab is discontinued at the time of the first cardiac symptoms, the damage can be reversible [44]. …”
Section: Breast Cancer and Cardiotoxicitymentioning
confidence: 99%
“…Anthracyclines and trastuzumab are both associated with cardiotoxicity [1]. Trastuzumab is associated with cardiotoxicity through a variety of HER2-related and unrelated mechanisms [4]. Concurrent use of anthracyclines and trastuzumab, while highly effective, are found to synergize in inducing cardiac damage [2].…”
mentioning
confidence: 99%